Signalpoint

← Full daily brief

Mass Tort brief

Mass Tort: Teva Resolves Patent Dispute, Abbott Settles Preterm Formula Claims

Teva settles generic drug litigation while Abbott reaches a $670 million infant formula settlement and Wix faces US securities claims.

Signalpoint TeamBrief

Mass Tort

Abbott's $670M settlement caps immediate trial losses — but over 12,000 infant formula claims still loom in federal court.

BackgroundParents sued formula makers alleging that specialized preterm infant formulas increased the risk of necrotizing enterocolitis in premature babies. Pediatric medical guidelines and warning labels on specialized infant nutrition are closely monitored by global health regulators.

Points
  1. The $670 million settlement covers roughly 2,000 individual claims without Abbott admitting legal liability, capping immediate courtroom financial exposures.
  2. The agreement halts pending appeals stemming from a $495 million jury verdict handed down in 2024, stabilizing near-term financial projections.
  3. Approximately 1,700 lawsuits representing 12,700 infants remain pending in federal multidistrict litigation in Illinois, leaving long-term systemic liability unresolved.
SourcesInsurance Journal: Abbott Agrees to $670 Million Settlement of Infant Formula Cases (opens in new tab)Seeking Alpha: Abbott in $670M settlement for some NEC infant formula claims (opens in new tab)

Mass Tort

A key bellwether case against tech giants collapsed before trial — delaying early jury verdicts on social media platform liability.

BackgroundOver 3,300 consolidated lawsuits across the United States allege social media algorithms intentionally foster addiction among minors. Bellwether trials are selected by courts to test evidence strength and establish settlement benchmarks.

Points
  1. The plaintiff dropped all claims without financial compensation weeks before trial proceedings were set to open, delivering a procedural victory to platform operators.
  2. The case was one of three primary bellwether trials chosen to test platform liability before state juries, temporarily deflecting broad social media litigation pressure.
  3. Two remaining bellwether trials scheduled for October will set early legal precedents for social media product liability and potential mass settlement structures.
SourcesBusinessWorld Online: US teen drops lawsuit against Meta, Google and Snap ahead of trial (opens in new tab)TNW: New Jersey teen drops claims against Meta, Google, and Snap weeks before trial (opens in new tab)

Mass Tort

Teva's settlement with Aurinia removes patent litigation exposure — locking in clear timelines for its generic drug pipeline.

BackgroundLupkynis is an approved treatment for active lupus nephritis, a serious autoimmune kidney condition. Generic drug developers routinely challenge brand patents in U.S. federal courts to establish predictable commercial launch dates.

Points
  1. Teva acknowledged the validity and enforceability of Aurinia's key Lupkynis patents expiring in late 2036, establishing clear long-term generic planning parameters.
  2. The settlement resolves pending litigation in U.S. District Court in New Jersey without trial or monetary damages, curbing ongoing legal expenses for the firm.
  3. Clarifying generic entry dates removes regulatory and legal uncertainty surrounding Teva's specialty US drug pipeline, allowing capital reallocation toward key growth assets.
SourcesFierce Pharma: Aurinia deal with Teva keeps Lupkynis generic in check until '36 (opens in new tab)Investing.com: Aurinia settles patent dispute with Teva over generic drug (opens in new tab)

Mass Tort

Wix faces US shareholder class action litigation over its AI growth statements — creating legal overhang for the Israeli web giant.

BackgroundPublic tech companies face heightened class action exposure under US federal securities laws when financial disclosures diverge from investor expectations. Tel Aviv-headquartered Wix is dual-listed on NASDAQ and the Tel Aviv Stock Exchange.

Points
  1. The lawsuit alleges misleading statements regarding commercial traction for Wix Harmony and Base44 AI tools, threatening investor confidence in new product lines.
  2. The class action sets a September 22 deadline for lead plaintiff applications in federal court, initiating formal consolidation of institutional investor claims.
  3. The litigation impacts equity holders across both US and Israeli stock exchanges, creating valuation overhang for the Tel Aviv-based web platform.
SourcesGuruFocus: WIX Investors Have Opportunity to Lead Wix.com Ltd. Securities Fraud Lawsuit (opens in new tab)

Unlock the full brief

Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.

Or read free in the appDownload on the App Store